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Borders: Spain and Atlantic Ocean
Includes Azores and Madeira Islands (Atlantic ocean)
Total area: 92,090 sq km
Population: 10,487,289 persons (December 2012)
Negative population growth rate: negative natural and migration 
growth rates.
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Portuguese National Program for Newborn Screening
•Congenital hypothyroidism (CH)
•ms/ms (24 IEM, PKU included)
•Cystic Fibrosis (CF, pilot study)
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Newborn Screening in Morocco - workshop II
Portuguese National Program for Newborn Screening
Defined by Health Minister as an integrated Program (2010)










(3rd – 6th days)
8 Treatment Centers
(Central Hospitals)
Newborn Screening in Morocco - workshop II
160.000
Nascimentos RN estudados
Non-mandatory, with 99.8% coverage
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Sample collection at hospital or health family centers (3rd-6th day)
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Average age for treatment beginning: 10.1 days
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Portuguese National Program for Newborn Screening
Results communication: 
•Normal cases – www.diagnosticoprecoce.org
•Non-urgent 2nd sample request (mail)
•Immediate sending to reference centers
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Method
Analysis of amino acids and acylcarnitines as butyl esters (Rashed et al., 1995)
(2 API 2000 triple quadrupole tandem mass spectrometers – Applied Biosystems)
NBS by ms/ms: 2004 - 2014
2nd tier test
Succinylacetone (Tyr>210 µM, modified from Allard et al., 2004)
Quality Control Programs
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NBS by ms/ms: 2004 - 2014







*Phenylketonuria (PKU) / HPA  
*Maple syrup urine disease (MSUD)  
Tyrosinemia type I  
Tyrosinemia type II  
Urea cycle disorders
*Citrullinemia type I  
*Argininosuccinate lyase deficiency (ASA)  
Arginase deficiency (ARG 1) 
NBS by ms/ms: 2004 - 2014
Homocystinuria (CBS deficiency)  
MAT I/III deficiency
Organic acid disorders
3-Methylcrotonyl-CoA carboxylase def. (3MCC)
*Isovaleric aciduria (IVA) 
*Propionic aciduria (PA) 




*Methylmalonic aciduria (mut-/0 and Cbl C, D) 
*Glutaric aciduria type I (GA1) 






Carnitine transport defect (CUD) 
*Started in 2004
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Disorders Positive screening criteria
Phenylketonuria (PKU) / 
Hyperphenylalaninaemia
Phe >150μM and Phe/Try >1,5
NBS by ms/ms: 2004 - 2014
Amino acid disorders and urea cycle disorders
Maple syrup urine disease (MSUD) XLeu >342μM and Val >350μM
Tyrosinemia type I Tyr >210μM and succinylacetone (+)
Tyrosinemia type II Tyr >850μM and succinylacetone (-)
Homocystinuria (CBS deficiency) Met >57μM
Methionine adenosyltransferase deficiency
(MAT I/III deficiency) 
Met >57μM




Arginase deficiency Arg >50μM
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Disorders Positive screening criteria
3-Methyl crotonyl-CoA carboxylase deficiency 
C5OH >1μM
NBS by ms/ms: 2004 - 2014
Organic acid disorders
(3MCCD)
Isovaleric aciduria (IVA) C5 >2μM
Propionic aciduria (PA) C3 >5,2μM and C3/C2 >0,3
Methylmalonic aciduria (mut -/0) C3 >5,2μM and C3/C2 >0,3
Glutaric acidemia type I GA 1) C5DC (>0.2μM)
C3 >5,2μM, C3/C2 >0,3 and C3/Met 
Methylmalonic aciduria (Cbl C, D)
>0,4
3-Hydroxy-3-methylglutaryl CoA lyase deficiency 
(3HMG)
C5OH >1μM and C6DC >0,07μM
Malonic aciduria C3DC >0,4μM
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Disorders Positive screening criteria
Medium-chain acyl-CoA dehydrogenase deficiency
C8 >0,3μM and C8/C10 > 2,5
NBS by ms/ms: 2004 - 2014
Fatty acid oxidation disorders
(MCAD)
Long-chain 3-OH acyl-CoA dehydrogenase deficiency 
(LCHAD)
C16OH >0,10μM, C18:1OH >0,07μM,
C18OH >0,06μM and C16OH/C16 
>0,04
Multiple acyl-CoA dehydrogenase deficiency (MADD) Multiple elevations from C4 to C18
Carnitine transport defect (CUD) C0 <7μM
Very-long-chain acyl-CoA dehydrogenase deficiency 
(VLCAD)
C14:1 >0,46μM and C14:2 >0,17μM
Carnitine palmitoyl-transferase I deficiency (CPT I) C0/(C16+C18) >30
Carnitine palmitoyl-transferase II deficiency (CPT II)
C0/(C16+C18)<3 and
(C16+C18:1)/C2>0.5
Short-chain 3-OH acyl-CoA dehydrogenase deficiency 
(SCHAD)
C4OH >1,0μM
Confirmation of positive cases
•Plasmatic aminoacids analysis (ionic change chromatography)
NBS by ms/ms: 2004 - 2014
•Urinary organic acids (GC-MS)
•Acylcarnitines (dry blood spots, ms/ms)
•Molecular analysis
•Urinary orotic acid (HPLC) 
•Urinary succinylacetone (GC-MS)






Amino acid disorders 127 1: 6 460
Phenylketonuria (PKU) 65 1: 12 622
Hyperphenylalaninaemia 20 1: 41 022
ms/ms positive cases and birth prevalence: 2004-2014
Maple syrup urine disease (MSUD) 4 1: 205 108
Tyrosinemia type I 6 1: 136 739
Tyrosinemia type III 1 1: 820 433
Homocystinuria (CBS deficiency) 2 1: 410 217
Methionine adenosyltransferase deficiency (MAT I/III 
deficiency) 
29 1: 28 291
Urea cycle disorders 16 1: 51 277
Citrullinemia type I 9 1: 91 159
Argininosuccinate lyase deficiency 2 1: 410 217
Arginase deficiency 5 1: 164 087






Organic acid disorders 66 1: 12 431
ms/ms positive cases and birth prevalence: 2004-2014
3-Methyl crotonyl-CoA carboxylase deficiency (3MCCD) 23 1: 35 671
Isovaleric aciduria 4 1: 205 108
Holocarboxylase synthetase deficiency 2 1: 410 217
Propionic aciduria 3 1: 273 478
Methylmalonic aciduria (mut-/0) 4 1: 205 108
Glutaric aciduria type I 12 1: 68 369
Methylmalonic aciduria (Cbl C/ D) 8+1 1: 91 159
3-Hydroxy-3-methylglutaryl CoA lyase deficiency 8 1: 102 554
Malonic aciduria 1 1: 820 433






Fatty acid oxidation disorders 133 1: 6 169
Medium-chain acyl-CoA dehydrogenase deficiency
(MCAD)
98 1: 8 372
ms/ms positive cases and birth prevalence: 2004-2014
Long-chain 3-OH acyl-CoA dehydrogenase deficiency 
(LCHAD)
7 1: 117 205
Multiple acyl-CoA dehydrogenase deficiency (MADD) 5 1: 164 087
Carnitine transport defect (CUD) 8 1: 102 554
Very-long-chain acyl-CoA dehydrogenase deficiency 
(VLCAD)
8 1: 102 554
Carnitine palmitoyl-transferase I deficiency (CPT I) 2 1: 410 217
Carnitine palmitoyl-transferase II deficiency (CPT II) 3 1: 273 478
Short-chain 3-OH acyl-CoA dehydrogenase deficiency 
(SCHAD)
2 1: 410 217
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ms/ms positive cases and birth prevalence: 2004-2014
Screened Newborns (ms/ms) Positive cases Birth prevalence
820 433 342 1: 2 399
Number of samples 820.433
Sensitivity 99.42%
Specificity 99.81%
NBS by ms/ms – Performance metrics0
Newborn Screening in Morocco - workshop II
Positive Predictive Value (PPV) 18%
Positive detection rate 1: 2.399
False positive rate 0.19%
Major causes for false positive cases
C5↑
C3↑
NBS by ms/ms: 2004 - 2014
C5DC↑ (premature NB)
Arg↑ (premature NB)
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Additional findings (ms/ms) 
3MCCD mothers 9
CUD mothers 4
GA 1 mothers 3
NBS by ms/ms: 2004 - 2014
Galactosemias (Phe + Tyr ↑) 5
Additional findings (family studies)
MCAD mothers (2) and brothers 
MAT I/III deficient relatives (>30)
MADD father (1)
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False negative results
NBS by ms/ms: 2004 - 2014
Methylmalonic aciduria (Cbl D)




C0= 15.1µM (N: 9.1-68)
C2 =  17.2µM (N: 7.0-49)








Cit= 24 µM (N<50)
ASA= 0.26 µM (N<1.1)
C16=  2.26µM(N: 0.83-7.99)
C18=  1.0µM(N: 0.23-2.28)
C18:1=1.51µM(N: 0.34-3.4)
C18:2= 0.13µM(N: 0-0.8)
C0/(C16 + C18)= 4.6(N: 3-30 )
(C16+C18:1)/C2= 0.22(N <0.5)
(p.S113L/ p.S113L) (p.R12Q/ p.R12Q)




NBS by ms/ms: 2004 - 2014
Urea Cycle disorders - 5%
Organic acid
disorders - 19%
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PKU / HPA
MSUD
NBS by ms/ms: 2004 - 2014
Amino acid disorders






Citrullinemia type I 




Arginase deficiency (ARG 1)
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NBS by ms/ms: 2004 - 2014
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3-Methylcrotonyl-CoA 
carboxylase def. (3MCC)









Glutaric aciduria type I (GA1)
(E37X)





Methylmalonic aciduria (Cbl C/D) – 14%
(Type Cbl C: c.271dupA)
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Portuguese National Program for Newborn Screening
Total birth prevalence for all screened disorders: 1: 1.659
Total positive cases: 1.727
Newborns Disorders Birth prevalence
3.375.266 PKU / HPA 1: 10.459  
3.343.098 HC 1: 2.986 
820.433 IEM 1: 2.399 
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Foto da Equipa 
IEM screening group (ms/ms)





Newborn Screening, Genetics and Metabolism Unit
Human Genetics Department
National Institute of Health Dr Ricardo Jorge
Porto - Portugal
Total number of Screened Newborns: 3.374.671
Total number of positive cases: 1.727







3.374.671 324 1 : 10.415
CH
1981 – 2013
3.342.429 1.123 1 : 2.976
TSH 3rd-5th days
< 10 mUI/L
10 - 20 
mUI/L





































AutoDELFIA® Neonatal TSH kit - PerkinElmer
CH Screening
T4 quantification
AutoDELFIA® Neonatal T4 kit – PerkinElmer
Total number of Screened Newborns: 3.374.671
Total number of positive cases: 1.727







3.374.671 324 1 : 10.415
CH
1981 – 2013
3.342.429 1.123 1 : 2.976
Neonatal Screening for CF
IRT ≥ 150 ng/mL
2ndIRT  (ng/ml)
IRT <65 ng/mL 100 ng/mL ≤ IRT< 150 ng/mL
CF not probable
65 ng/mL ≤ IRT< 100 ng/mL
1st IRT (sampling time: 3 to 6 days)
PAP PAP
PAP<0,5ng/mL PAP≥0,5ng/mLPAP≥1,6ng/mLPAP<1,6ng/mL
CF not probable CF not probable2
nd IRT  (ng/ml) 2nd IRT  (ng/ml)
2nd IRT (sampling time: 2 to 3 weeks) 
IRT <50 ng/mL IRT ≥ 50 ng/mL














AutoDELFIA® Neonatal IRT kit - PerkinElmer
FQ Neonatal Screening
PAP quantification
Kit MucoPAP-F - Dynabio
(adapted to system DELFIA® - Perkin Elmer)
Molecular study
Elucigene CF-EU2v1 (50 mutations)
Screened NB 80 000
Confirmed patients 11
Birth prevalence 1: 7 273
FQ Neonatal Screening
IRT > 65 ng/mL 665 (0,83%)
PNA (IRT+PAP ↑) 277 (0,35%)
2º IRT < 50 ng/mL 250 (0,31% false positives)
NB referred to sweat test 27
Confirmed patients 11
Waiting for confirmation 5










D1 (5d, 18d) 94 5,4 158 F508del/F508del
D2 (21d, --) 129 3,9 n.d. F508del/F508del
FQ Neonatal screening
D3 (6d, 14d) 210 >8,8 287 F508del/?
D4 (23d, 28d) 190 >8,8 195 F508del/F508del
D5 (3d, 13d) 260 4,3 344 F508del/F508del
D6 (4d, 27d) 266 >8,8 360 F508del/F508del
D7 (5d, 15d) 443 >8,8 480 F508del/F508del
D8 (4d, --) 202 2,7 n.d. F508del/N1303K
* If IRT<100ng/mL, PAP<1,6 ng/mL
D9 (2d, 5d) 101 >8,8 85 F508del/F508del
D10 (4d, 30d) 110 4,6 123 F508del/F508del
D11 (3d, 16d) 414 >8,8 265 F508del/F508del
